Application Methods: Immunofluorescence (Frozen), Immunohistochemistry (Paraffin)
Background: Adenosine Receptor A2a (A2AR) is a G-protein-coupled receptor (GPCR). As a member of the purinergic adenosine receptors (A1, A2, and A3), A2AR activates classic G-protein signaling pathways upon binding of adenosine (1). Adenosine is present in all cells and extracellular fluids. Adenosine signaling, via A2AR, is mobilized during both physiological and pathological conditions. For example, adenosine, via A2AR, modulates neuronal function, acting to fine-tune neuronal function (2). A2AR function is modulated, in part, by its ability to form functional heteromers with other GPCRs, including dopamine receptors (D1 and D3), metabotropic glutamate receptors (mGluR5), and others (3). In the brain, A2AR is enriched in the basal ganglia, suggesting that A2AR may be a potential drug target for neurodegenerative diseases like Parkinson’s disease, drug addiction, and psychiatric disorders (4). Outside of the brain, A2AR may act as an immune checkpoint molecule to maintain an immunosuppressive tumor microenvironment, an environment that exhibits relatively elevated adenosine levels (5, 6).
|Human, Mouse, Rat|
Application Methods: Immunofluorescence (Frozen), Immunoprecipitation, Western Blotting
Background: mGluR5, a metabotropic glutamate receptor, is a class C G protein-coupled receptor that signals through the Gaq/11-PLC-inositol 1,4,5 triphosphate pathway (1). mGluR5 is comprised of a large N-terminal extracellular domain, seven transmembrane domains, and a C-terminal intracellular domain. Glutamate binding to mGluR5 leads to an increase in intracellular calcium levels and stimulation of PKC activity (2). In neurons, mGluR5 is found in the post-synapse, in a complex with NMDA receptors, PSD-95, SHANK, and Homer (3). mGluR5 is also expressed in microglia and astrocytes (4). Neuronal mGluR5 has been shown to interact with amyloid beta oligomers, and mGluR5 antagonists exhibit neuroprotective effects (5) placing mGluR5 as a potential therapeutic target for Alzheimer’s disease. In glial cells, mGluR5 appears to play an anti-inflammatory role by negatively regulating the release of inflammatory factors (6).